Schroeder Thilo
Known title: DirectorCIK: 0001776412
Schroeder Thilo's purchase track record
How the stock did after each of Schroeder Thilo's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
7
of 7 since March 2, 2022
Stock higher 6 months later
57%
3 months: 14%
Median 6-month return
+5.3%
3 months: -12.4%
Beat the S&P 500
71%
median +11.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/5/2024 | RVMD | $60.00M | -17.1% | -15.0% | -2.2% |
| 3/7/2023 | RVMD | $14.15M | +9.8% | +37.0% | +12.8% |
| 7/22/2022 | RVMD | $5.00M | -16.8% | +23.1% | +0.3% |
| 3/28/2022 | RVMD | $18K | -25.0% | -25.6% | -20.1% |
| 3/18/2022 | RVMD | $9.77M | -12.1% | -1.3% | -13.2% |
| 3/10/2022 | RVMD | $1.09M | -8.2% | +5.3% | -5.9% |
| 3/2/2022 | RVMD | $9.08M | -12.4% | +10.4% | -9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
PMV Pharmaceuticals Adds Matt Eckler to Board. PMV Pharmaceuticals has appointed Matt Eckler, Ph.D., to its Board of Directors. This corporate update adds to the company's leadership team. The stock is currently trading near the top of its 52-week range, with an RSI of 69.0 indicating strong recent momentum.
Transaction History
| RVMD | ▲ Buy | Open Market | 543,478 | $25.0M | 12/5/2024 | View on chart |
| RVMD | ▲ Buy | Open Market | 760,869 | $35.0M | 12/5/2024 | View on chart |
| RVMD | ▲ Buy | Grant | 922,099 | — | 11/9/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 535,112 | — | 11/9/2023 | View on chart |
| RVMD | ▲ Buy | Open Market | 6,200 | $129K | 3/10/2023 | View on chart |
| RVMD | ▲ Buy | Open Market | 93,800 | $1.9M | 3/10/2023 | View on chart |
| RVMD | ▲ Buy | Open Market | 231,819 | $5.1M | 3/7/2023 | View on chart |
| RVMD | ▲ Buy | Open Market | 318,181 | $7.0M | 3/7/2023 | View on chart |
| RVMD | ▲ Buy | Open Market | 250,000 | $5.0M | 7/22/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 725 | $18K | 3/28/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 29,235 | $719K | 3/25/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 12,765 | $322K | 3/25/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 49,119 | $1.2M | 3/24/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 37,708 | $890K | 3/23/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 15,410 | $370K | 3/23/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 5,440 | $120K | 3/22/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 71,186 | $1.7M | 3/22/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 53,501 | $1.3M | 3/22/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 879 | $19K | 3/21/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 74,852 | $1.6M | 3/21/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 5,992 | $116K | 3/18/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 76,208 | $1.6M | 3/18/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 10,120 | $190K | 3/17/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 3,110 | $65K | 3/11/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 37,911 | $780K | 3/10/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 2,489 | $53K | 3/10/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 39,600 | $795K | 3/9/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 42,882 | $782K | 3/8/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 42,011 | $813K | 3/8/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 18,940 | $377K | 3/8/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 95,926 | $1.8M | 3/7/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 7,079 | $134K | 3/7/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 56,300 | $996K | 3/4/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 54,764 | $1.0M | 3/3/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 10,873 | $208K | 3/3/2022 | View on chart |
| RVMD | ▲ Buy | Open Market | 116,290 | $2.2M | 3/2/2022 | View on chart |
| PMVP | ▼ Sell | Open Market | 800 | $24K | 10/6/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 100 | $3K | 10/4/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 11,541 | $347K | 10/1/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 2,978 | $89K | 9/30/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 5,708 | $171K | 9/29/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 1,753 | $53K | 9/27/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 100 | $3K | 9/22/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 711 | $21K | 9/17/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 13,272 | $401K | 9/13/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 38,056 | $1.2M | 9/10/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 5,171 | $160K | 9/10/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 14,329 | $434K | 9/9/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 5,400 | $163K | 9/2/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 21,986 | $668K | 9/1/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 19,520 | $588K | 8/31/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 13,233 | $398K | 8/30/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 23,397 | $714K | 8/27/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 1,045 | $32K | 8/27/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 15,063 | $458K | 8/26/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 6,091 | $190K | 8/26/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 13,526 | $419K | 8/25/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 14,490 | $450K | 8/24/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 23,138 | $709K | 8/23/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 700 | $22K | 8/23/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 3,800 | $118K | 8/19/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 11,431 | $372K | 8/18/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 13,196 | $447K | 8/18/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 2,237 | $77K | 8/18/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 15,276 | $507K | 8/17/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 15,746 | $534K | 8/17/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 19,584 | $662K | 8/16/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 2,599 | $90K | 8/16/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 1,500 | $52K | 8/13/2021 | View on chart |
| PMVP | ▼ Sell | Open Market | 25,786 | $882K | 8/13/2021 | View on chart |
| RVMD | ▲ Buy | Open Market | 300,000 | $13.5M | 2/8/2021 | View on chart |
| RVMD | ▲ Buy | Open Market | 150,000 | $3.9M | 7/13/2020 | View on chart |
| RVMD | ▼ Sell | Other | 2,118,214 | — | 2/18/2020 | View on chart |
| RVMD | ▲ Buy | Open Market | 400,000 | $6.8M | 2/18/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.